Michael Bishop to Cell- and Tissue-Based Therapy
This is a "connection" page, showing publications Michael Bishop has written about Cell- and Tissue-Based Therapy.
Connection Strength
0.577
-
New hope to prevent ALL relapse after transplant. Blood. 2022 04 28; 139(17):2580-2581.
Score: 0.190
-
Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses. Leuk Lymphoma. 2021 06; 62(6):1497-1501.
Score: 0.174
-
Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. J Immunother Cancer. 2024 02 29; 12(2).
Score: 0.054
-
Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome. Blood Adv. 2023 09 12; 7(17):4765-4772.
Score: 0.052
-
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma. Blood. 2021 06 17; 137(24):3454-3459.
Score: 0.045
-
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol. 2018 04; 15(4):218.
Score: 0.035
-
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. Biol Blood Marrow Transplant. 2014 Jan; 20(1):4-13.
Score: 0.026